European Journal of Health Economics

Papers
(The H4-Index of European Journal of Health Economics is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Education and medication use later in life and the role of intelligence72
Beyond 10-year lead-times in EQ-5D-5L: leveraging alternative lead-times in willingness-to-accept questions to capture preferences for worse-than-dead states and their implication67
Costing methodologies in European economic evaluation guidelines: commonalities and divergences59
Should Scotland provide genome-wide sequencing for the diagnosis of rare developmental disorders? A cost-effectiveness analysis55
Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries55
Correction to: Geographic distribution of physicians in Portugal44
Characteristics and health care costs in patients with a diagnostic imaging for low back pain in Switzerland40
Psychometric properties and general population reference values for PROMIS Global Health in Hungary39
Pragmatic randomized controlled trial comparing a complex telemedicine-based intervention with usual care in patients with chronic conditions34
Comparing the measurement properties of the EQ-5D-Y-3L, EQ-5D-Y-5L and CHU9D in children and adolescents: a measurement property study32
The hidden cost of sophistication: economic complexity and obesity31
Patient-level cost analysis of subfertility pathways in the Dutch healthcare system28
Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland28
Cost-effectiveness of transcatheter aortic valve implantation in patients at low surgical risk in France: a model-based analysis of the Evolut LR trial28
Prescription opioids and economic hardship in France26
Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan25
Cost awareness among intensivists in their daily clinical practice: a prospective multicentre study24
The employment situation of people living with HIV: a closer look at the effects of the 2008 economic crisis23
Workload and short sickness absences in a cohort of Finnish hospital employees23
Cost-effectiveness analysis of vaborem for the treatment of carbapenem-resistant Enterobacteriaceae-Klebsiella pneumoniae carbapenemase (CRE-KPC) infections in the UK23
From test to rest: evaluating socioeconomic differences along the COVID-19 care pathway in the Netherlands22
Expensive today but cheaper tomorrow: lifetime costs of an active middle ear implant compared to alternative treatment options22
0.049798011779785